Ultima Genomics Appoints Francisco De La Vega to Lead Germline Genomics

May 19, 2026
Ultima Genomics has appointed Francisco De La Vega as Vice President of Germline Genomics and Distinguished Scientific Fellow. He will guide the company’s efforts in inherited genome analysis and expand applications of its sequencing technology for genetic disease research and clinical use.

Ultima Genomics announced in a press release that Francisco De La Vega has joined the company as Vice President of Germline Genomics and Distinguished Scientific Fellow. He brings more than 25 years of experience in human genetics, computational biology, and bioinformatics.

De La Vega will lead Ultima’s efforts in inherited genome analysis to advance research in genetic diseases, population health, and personalized medicine. He previously held senior positions at Applied Biosystems, Fabric Genomics, Tempus AI, and Galatea Bio, contributing to major projects such as the 1000 Genomes Project and the International Cancer Genome Consortium.

Ultima stated that De La Vega’s appointment supports its strategy to expand germline genome sequencing applications using its UG200 instrument and Solaris 2.0 chemistry. His experience in developing genetic analysis technologies and bioinformatics tools will help the company enhance scalability and accuracy across research and clinical genomics initiatives.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

05/19
InterVenn Biosciences Adds Alec Ford and Mitch Levine to Board of Directors
05/19
Sanyou Biopharmaceuticals Upgrades AI-STAL Platform for Intelligent Biologics Discovery
05/19
OMNY Health Expands Data Network and Introduces Oncology Research Suite
05/19
UNC Greensboro Receives $2 Million for NC BioMISSION Workforce Program
05/19
Vortex Imaging Raises $12 Million to Advance Computational Ultrasound System

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like